Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis

被引：15

作者：

Yuan, Meng ^{[1
]}

Zhai, Yirui ^{[1
]}

Men, Yu ^{[1
,2
]}

Wang, Jianyang ^{[1
]}

Deng, Lei ^{[1
]}

Wang, Wenqing ^{[1
]}

Bao, Yongxing ^{[1
]}

Yang, Xu ^{[1
]}

Sun, Shuang ^{[1
]}

Ma, Zeliang ^{[1
]}

Liu, Yunsong ^{[1
]}

Wang, Jun ^{[3
]}

Zhu, Hui ^{[4
]}

Hui, Zhouguang ^{[1
,2
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Radiat Oncol Natl, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept VIP Med Serv, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China

[3] Hebei Med Univ, Dept Radiat Oncol, Hosp 4, Shijiazhuang, Hebei, Peoples R China

[4] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China

来源：

THORACIC CANCER | 2021年 / 12卷 / 23期

关键词：

chemoradiotherapy; endostar; meta-analysis; NSCLC; RECOMBINANT HUMAN ENDOSTATIN; PHASE-III TRIAL; SOUTHWEST-ONCOLOGY-GROUP; CONSOLIDATION DOCETAXEL; RADIOTHERAPY; BEVACIZUMAB; CISPLATIN; ETOPOSIDE; CHEMORADIATION; RADIORESPONSE;

D O I：

10.1111/1759-7714.14188

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background We aimed to clarify the benefits of the addition of rh-endostatin into concurrent chemoradiotherapy (CCRT) versus CCRT alone for locally advanced non-small cell lung cancer (NSCLC) by a meta-analysis. Methods PubMed, Embase, Cochrane Central Register of Controlled Trials, Wanfang and Chinese National Knowledge Infrastructure (CNKI) were systematically screened from inception to November 2020 using the prespecified terms. Prospective trials (evaluating or) comparing the efficacy of endostar combined with CCRT and CCRT for locally advanced NSCLC were included. The primary endpoints were risk ratios (RRs) for objective response rate (ORR) and disease control rate (DCR). The secondary endpoints were RRs for overall survival (OS) and adverse events (AEs). Results Ten studies with 716 patients were included in this meta-analysis. Endostar combined with CCRT significantly improved ORR and DCR compared with CCRT. The RRs of ORR and DCR for endostar combined with CCRT versus CCRT were 1.263 (95% CI: 1.137-1.403, p < 0.001) and 1.274 (95% CI: 1.124-1.444, p < 0.001), respectively. Endostar combined with CCRT significantly improved one-year survival rate compared with CCRT with pooled RR = 1.113 (95% CI: 1.006-1.231, p = 0.038). Endostar combination treatments had similar incidences of main adverse events compared with CCRT (p > 0.05). Conclusion Endostar combined with CCRT is associated with significantly higher ORR, DCR and survival rate than CCRT with similar incidences of main adverse events in NSCLC.

引用

页码：3208 / 3215

页数：8

共 39 条

[1] Concurrent cisplatin, etoposide, and chest radiotherapy in Pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group Phase II Study, SWOG 9019 [J].